Table 1.
Features of induced pluripotent stem cell (iPSC) lines generated for testing teratoma growth in autologous recipients.
| iPSC line | Expression of pluripotency genes (mRNA) | Expression of pluripotency markers (protein) | In vitro differentiation (expression of marker genes) | Teratoma in immunodeficient recipients (RAG2−/−) | Teratoma in autologous recipient (C57BL/6J) | Teratoma in syngeneic Recipients (C57BL/6J) | Teratoma in major histocompatibility complex-matched allogeneic recipients (129 Sv, H2b) |
|---|---|---|---|---|---|---|---|
| 0–3 | Yes | Yes | Yes | 2/3 | Yes | 2/4 | 0/3 |
| 1–2 | Yes | Yes | Yes | 4/4 | Yes | 2/4 | 0/3 |
| 6–5 | Yes | Yes | Yes | 0/41 | Yes | 0/4 | 0/3 |
| 8–7 | Yes | Yes | Yes | 4/4 | No | 2/4 | 0/3 |
| 9–2 | Yes | Yes | Yes | nt2 | No | nt | nt |
1The iPSC 6–5 cells formed teratomas in two of two RAG2−/−γc−/− mice, which lack in addition to B and T cells also NK cells, and were thereby confirmed to be pluripotent.
2The abbreviation nt indicates not tested.